Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05105100 · ClinicalTrials.gov registry record
Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma
A clinical trial, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 25
- Enrollment target
NCT05105100 is a clinical trial that has completed, run by University of California, San Francisco. The registered enrollment target is 25 participants.
The verdict
NCT05105100 has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
This is a non-therapeutic study assessing peripheral T cell determinants of response and resistance to immunotherapy in patients with advanced melanoma.The hypothesis is that systemic T cells traffic into the tumor microenvironment (TME) can predict response and resistance to immunotherapy. These systemic tumor directed T cells can be defined by tumor/blood small conditional RNA (scRNA) using T cell receptor (TCR) as a barcode and can help predict response to Programmed death-1 (PD-1) therapy.
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-10-29 |
| Est. Completion | 2025-09-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05105100
The ClinicalTrials.gov registry entry for NCT05105100 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT05105100 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05105100 about?
NCT05105100 is a clinical study titled "Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma". This is a non-therapeutic study assessing peripheral T cell determinants of response and resistance to immunotherapy in patients with advanced melanoma.The hypothesis is that systemic T cells traffic into the tumor microenvironment (TME) can predict response and resistance to immunotherapy. These sy...
What is the current status of trial NCT05105100?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2021-10-29. Estimated completion is 2025-09-15.
What interventions are being tested in trial NCT05105100?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT05105100?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.